HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims

This article was originally published in The Rose Sheet

Executive Summary

Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.

You may also be interested in...

ASA Ruling On My Perfect Eyes Reinforces Opportunity For Instant Skin Care

The Perfect Cosmetics Company’s clinical trial evidence is sufficient in the Advertising Standards Authority’s view to support the claim that eye-area wrinkles “virtually disappear” following use of its My Perfect Eyes formula. Products of its ilk could be relatively safe plays from a regulatory perspective in an otherwise challenging category and appeal to younger consumers seeking instant skin-care solutions.

‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection

Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.

FDA: Cosmetic Warning Letters Carry Same Weight Regardless Of Issuing Office

Around 96% of warning letters for excessive cosmetics claims in 2016 have issued from FDA district offices as opposed to CFSAN headquarters, representing a marked shift from previous years. The agency stresses, however, that the source of a warning letter has no bearing on its implications.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts